Navigation Links
Accera, Inc. Announces Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting

pound's disease modifying potential. Taken in addition to an existing AD treatment, AC-1202 was well tolerated, making it a promising co-therapeutic candidate for the chronic treatment of the disease.

Dr. Lauren Costantini is presenting the abstract, "Clinical Efficacy of AC-1202 in Mild to Moderate Alzheimer's Disease" at the Late Breaking Science session today at 3:45 p.m. EDT. The plenary session will be held at 5:15 p.m. EDT on Friday, May 4.

The trial was conducted at 25 centers across the United States, and all subjects were given the opportunity to participate in a six-month open-label extension upon completion of the three-month blinded study. The results of the open-label extension will be presented at the Alzheimer's Association's International Prevention Conference in early June.

About AC-1202

Brain imaging techniques performed on AD patients reveal a dramatically decreased uptake of glucose, the brain's preferred source of energy. AC-1202 is an orally available, liquid compound that is efficiently converted by the liver into ketone bodies, an alternative energy source that the brain can metabolize even when it cannot process glucose. Thus preserving the glucose- deprived brain cells, AC-1202 has disease modifying potential in AD and a number other neurodegenerative diseases characterized by neuronal metabolism. The potentially neuroprotective mechanism of this first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson's disease, and canine cognitive dysfunction.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biopharmaceutical company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, AC-1202, is a first- in-class molecule currently in Phase II clinical trials for Alzheimer's disease and age-associated memory impairment. A key element of Accera's strategy is to develop AC-1202 and other small molecule com
'"/>




Page: 1 2 3

Related medicine technology :

1. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:5/17/2013)... , Puerto Rico , May 17, ... central and western Puerto Rico , Caribbean ... PR) Center has improved its radiation therapy capabilities with the ... Puerto Rico . Versa HD offers clinicians ... range of tumors throughout the body, while also enabling treatment ...
(Date:5/17/2013)... , May 17, 2013  PENTAX Medical, a ... Medical, a global leader in ultrasound imaging, recently ... companies to enable further innovation in the development ... Hitachi-Aloka ultrasound systems and PENTAX Medical endoscopic portfolio ... families of EUS systems. This agreement will continue ...
(Date:5/17/2013)... May 17, 2013 Oramed Pharmaceuticals ... oral drug delivery systems, announced today that the United ... Company,s Investigational New Drug application(IND) for ORMD-0801, its oral ... have the FDA clearance to proceed," stated ... trial is a major milestone for Oramed and we ...
Breaking Medicine Technology:Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3
... LUND, Sweden, July 3 ,ThromboGenics NV (Euronext Brussels: THR) ... have started,recruitment of a second cohort of patients for ... recruitment of the first cohort of 100,patients ahead of ... being developed for the prevention of deep vein thrombosis ...
... The largest study of,the genetics of schizophrenia ever undertaken ... the human genome (SNPs) linked to,risk of the disease. The ... from deCODE genetics (Nasdaq: DCGN ), analyzed the genomes ... is published today in the online edition of Nature. , ...
Cached Medicine Technology:ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 2ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 3ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 4ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 5deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5
(Date:5/18/2013)... 2013 Dr. Robert Tracey, an area leader ... employs his knowledge of the root causes of sleep apnea ... May being Better Sleep Month, Dr. Tracey points out estimates ... sleep disorder, and sleep apnea is one of the most ... will essentially stop breathing at different times while sleeping. When ...
(Date:5/18/2013)... Wisconsin (PRWEB) May 18, 2013 Scott Tischler ... in 90 days. These five keys to losing weight played ... help and support of Scott Tischler, Troy was able to ... that any weight loss program should be approached with caution ... pain. These are the five keys to weight loss that ...
(Date:5/18/2013)... CA (PRWEB) May 18, 2013 John Ravera, ... announced the addition of a new member to his dental ... has worked in the field for over 10 years. She ... with honors, and was elected a member of Sigma Pi ... hygiene profession. Marino enjoys working with patients of all ages, ...
(Date:5/18/2013)... 2013 Kimono condoms assorted sampler ... condom store recently announced. Condomania recently added new ... selection of condoms from all over the world. ... to try different condom styles from one of the ... classic comfortable shape and secure, the new packs contain ...
(Date:5/18/2013)... May 18, 2013 According to the the ... as Toxic Epidermal Necrolysis, is a severe allergic reaction usually ... flu-like symptoms but it can quickly advance causing blistering and ... even cause death. SJS can develop at any time ... the former NBA player, Manute Bol, passed away after he ...
Breaking Medicine News(10 mins):Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 2Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 3Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2Health News:Kimono Condoms Assorted Sampler Packs Now Available at Condomania 2Health News:Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome 2
... a state of serious impairments in both learning ability ... one of the most prevalent conditions in child psychiatry, ... adulthood. ADHD is conservatively estimated to occur in 3,07,5% ... permissive criteria yield estimates of up to 17% (Barbaresi ...
... Just one week after,Cover All Pennsylvanians, the ... the General Assembly, Governor Edward G.,Rendell today visited ... "Tour to,Insure." The five-day, nine-stop tour has highlighted ... coverage. The Lehigh Valley has nearly 37,000,uninsured adults., ...
... no difference in motorists, reaction times , , SATURDAY, Oct. ... pain medications such as morphine does not impair a ... at Rush University Medical Center in Chicago compared two ... morphine and 49 who weren,t taking any pain medication. ...
... Holdings, Inc. (Nasdaq: NHWK ), a leading provider ... today announced that,it will host a conference call on ... to review the company,s third quarter results. Conference ... call will be held on Wednesday, October,31, 2007 at ...
... Medical Injustice, Will Challenge,Corporate-Backed Proponents of "Health Courts", ... Dale Nance, co-author of the groundbreaking new report ... the featured speakers at a,patient safety forum in ... debate the merits and weaknesses of the health ...
... SAN DIEGO, Oct. 12 MediKeeper,( http://www.medikeeper.com ), ... and wellness industry, has closed its Series A ... MediKeeper was started in 2003 by a ... of making medical records secure, mobile,and accessible online. ...
Cached Medicine News:Health News:Computerized training of working memory is a promising therapeutic strategy in ADHD 2Health News:Computerized training of working memory is a promising therapeutic strategy in ADHD 3Health News:Governor Rendell's 'Tour to Insure' Urges Passage of Plan to Give Access to Affordable Health Insurance 2Health News:Governor Rendell's 'Tour to Insure' Urges Passage of Plan to Give Access to Affordable Health Insurance 3Health News:Morphine Painkillers Won't Impair Driving 2Health News:NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call 2Health News:'Health Courts' Critic to be Featured Speaker at Wyoming Patient Safety Panel 2Health News:MediKeeper Closes Series A Financing Round with PacifiCap as Lead Investor 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: